{"id":572523,"date":"2026-07-28T18:48:09","date_gmt":"2026-07-28T18:48:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/572523\/"},"modified":"2026-07-28T18:48:09","modified_gmt":"2026-07-28T18:48:09","slug":"optima-af-1-month-vs-12-month-dual-antithrombotic-therapy-post-pci","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/572523\/","title":{"rendered":"OPTIMA-AF: 1-Month vs. 12-Month Dual Antithrombotic Therapy Post PCI"},"content":{"rendered":"<p>Only <a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(26)00665-3\/abstract\" title=\"Protected by Check Point: https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(26)00665-3\/abstract\" target=\"_blank\" rel=\"nofollow noopener\">one  month of dual antithrombotic therapy followed by direct oral anticoagulant  (DOAC) monotherapy<\/a> proved to be noninferior in terms of efficacy and  superior in terms of bleeding outcomes to the standard 12-month dual  antithrombotic therapy post PCI among patients with atrial fibrillation (AFib),  according to results of the OPTIMA-AF trial published July 15 in The Lancet. <\/p>\n<p>In this active-control trial, 1,088  patients across 75 sites in Japan were randomized to either one month of dual  antithrombotic therapy (DOAC + P2Y12 inhibitor) followed by DOAC monotherapy or  12 months of dual antithrombotic therapy following PCI with intravascular  imaging. Of the patients, 1,079 were included in the final analysis: 542 in the  one-month arm and 537 in the 12-month arm. Median age was 76 years and 21% were  women. Most had chronic coronary syndrome (94%), and 48% had paroxysmal AFib,  21% had persistent AFib and 30% had long-standing persistent AFib. Median CHADS2  score and median HAS-BLED score were both 2.<\/p>\n<p>Results at a median follow-up of  540 days showed that the primary efficacy endpoint, a composite of all-cause  death or thromboembolic events, occurred in 29 patients in the one-month arm  vs. 23 in the 12-month arm (5.4% vs. 4.3%; absolute difference, 1.1 percentage  points; hazard ratio [HR], 1.25) and the primary safety endpoint, major or  clinically relevant bleeding, occurred in 24 vs. 47 patients (4.5% vs. 8.8%;  absolute difference, \u20134.4 percentage points; HR, 0.50; p=0.0041 for  superiority).<\/p>\n<p>All-cause mortality was numerically  higher in the one-month arm (4.1% vs. 2.8%), driven primarily by  noncardiovascular deaths. Incidence of major bleeding was similar between the  two (HR, 0.77), and clinically relevant nonmajor bleeding was lower in the one-month  arm (HR, 0.26).<\/p>\n<p>\u201cBecause the observed event rates  were lower than anticipated under a fixed non-inferiority margin, efficacy  estimates warrant cautious interpretation,\u201d write investigators Yohei  Sotomi, MD, FACC, et al. \u201cFurther adequately powered trials are needed to  clarify applicability in acute coronary syndrome populations and in clinically  important subgroups.\u201d<\/p>\n<p>Although they ask for additional  data from more diverse populations, Gregory Y. H. Lip, MD, FACC, and Lukasz  Ku\u017ama, MD, PhD, call the trial potentially practice-changing in <a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(26)00747-6\/abstract\" title=\"Protected by Check Point: https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(26)00747-6\/abstract\" target=\"_blank\" rel=\"nofollow noopener\">an  editorial comment<\/a>, writing that it \u201cnicely illustrates that less is more,  especially in regard to the beneficial effect of less bleeding without an  increase in thromboembolism by shortening the use of dual therapy.\u201d<\/p>\n<p>&#13;<br \/>\n        Keywords: &#13;<br \/>\n        Atrial Fibrillation, Fibrinolytic Agents, Percutaneous Coronary Intervention, Anticoagulants&#13;\n     <\/p>\n","protected":false},"excerpt":{"rendered":"Only one month of dual antithrombotic therapy followed by direct oral anticoagulant (DOAC) monotherapy proved to be noninferior&hellip;\n","protected":false},"author":2,"featured_media":59664,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[103,61,60],"class_list":["post-572523","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-ie","tag-ireland"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/572523","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=572523"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/572523\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/59664"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=572523"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=572523"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=572523"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}